Skip to main content

Recent Publications

Browse recent studies from the Lou and Jean Malnati Brain Tumor Institute to learn more about our cutting-edge research.

  1. Li J, Wang X, Tong L, Feng B, Shih LK, Markwell SM, Nuszen H, Gruchala T, Lam NG, Basakis P  et al.  The perinecrotic niche of glioblastoma drives tumor-associated macrophage polarization and immunosuppression via podoplanin-mediated CLEC5A activation.  J Clin Invest  2026 Jul 15;136(14). pii:e199228
  2. Huang S, Lian Z, Jia D, Sun K, Li X, Liu J, Wang Y, Jiang C, Zhu F, Ding Z  et al.  BrainSeg: a generalized framework for comprehensive multimodal brain tissue segmentation, parcellation, and lesion labeling.  NPJ Digit Med  2026 Jul 10;. doi:10.1038/s41746-026-02894-x
  3. Song R, Liu L, Ofori-Apau J, Hojo E, Mirza M, Huston J, Gondi V, Khan OH  The clinical utility of magnetic resonance elastography in differentiating tumor recurrence from pseudoprogression in glioblastoma.  Magn Reson Imaging  2026 Jul 10;133:110746. doi:10.1016/j.mri.2026.110746
  4. Radaelli S, Frezza AM, Fossati P, Baldi GG, Akiyama T, Asencio JM, Bolle S, Bovee JVMG, Caraceni AT, Cote GM  et al.  Global Consensus on the Management of Primary Localized Chordoma.  JAMA Oncol  2026 Jul 09;. doi:10.1001/jamaoncol.2026.2054
  5. Baumert BG, Hegi ME, van den Bent MJ, von Deimling A, Gorlia T, Hoang-Xuan K, Brandes AA, Sargos P, Taphoorn MJB, Vauleon E  et al.  Temozolomide Versus Radiotherapy as First-Line Therapy for Low-Grade Glioma: Mature Results of a Randomized Phase III Trial (EORTC 22033-26033/NCIC-CTG/TROG/MRC-CTU).  J Clin Oncol  2026 Jul 02;:JCO2502735. doi:10.1200/JCO-25-02735
  6. Singh R, Koempel A, French B, Crawford C, Perlow HK, Rauh S, Kutuk T, Beyer S, Grecula J, Blakaj D  et al.  Improved Progression-Free Survival Following Dose-Escalated Versus Standard-Dose Postoperative Radiation Therapy for High-Risk Meningiomas: An International Multicenter Individual Patient-Level Meta-Analysis (FIRESTORM).  Int J Radiat Oncol Biol Phys  2026 Jul 01;125(3):696-705. doi:10.1016/j.ijrobp.2026.03.036
  7. Weber-Levine C, Xia Y, Al-Mistarehi AH, Jiang K, Mendelson BZ, Antar A, Ksabi NL, Zaitoun KJ, Papali P, Neerumalla S  et al.  The Impact of Expansile Duraplasty After Resection of Intramedullary Astrocytomas.  Oper Neurosurg  2026 Jul 01;31(1):36-49. doi:10.1227/ons.0000000000001762
  8. Kim KS, Zhang J, Arrieta VA, Dmello C, Grabis E, Yabo YA, Wang S, Habashy K, Duffy J, Zhao J  et al.  Glioma-intrinsic MAPK/ERK signaling promotes immunotherapy efficacy through T cell infiltration and interferon responses.  Nat Commun  2026 Jun 25;. doi:10.1038/s41467-026-74124-7
  9. Walker MN, Hu B, Cheng SY, Song X  Stepwise Protocol for Alternative Splicing Analysis in Single-Cell SMART-Seq2 RNA-Seq Data.  Bio Protoc  2026 Jun 20;16(12):e5735. pii:e5735
  10. Nathan CL, Ghandour D, Cunningham EM, Lukas RV, Sullivan J, Sachdev S, Templer JW  Epilepsy characteristics and outcomes in patients with pleomorphic xanthoastrocytomas.  J Neurooncol  2026 Jun 19;178(3). pii:72
  11. Mooney R, Ngai G, Kaur G, Kang EY, Lara J, Abd El-Fattah EE, Huang P, Flores L, McDonald M, Talley M  et al.  Neural stem cell delivery of oncolytic CRAd-S-pk7 immunotherapy for stage 3 ovarian cancer: Dose-regimen studies.  Mol Ther Oncol  2026 Jun 18;34(2):201219. pii:201219
  12. Fares J, Ahrendsen JT, Congivaram HT, Santana-Santos L, Oyon D, Dixit K, Youngblood MW, Chandler JP  CLIP2::MET fusion identifies a molecularly distinct glioneuronal tumor.  Discov Oncol  2026 Jun 17;. doi:10.1007/s12672-026-05421-2
  13. Li X, Xu J, Du G, Jia X, Zhao D, Zhou C, Xiao K, Gu J, Zhu J, Shang X  Accurately Deciphering Tissue Heterogeneity From Spatial Multi-Modal and Multi-Omics With STransformer.  Adv Sci (Weinh)  2026 Jun 09;:e75969. pii:e75969
  14. Khalifeh JM, ElNemer W, Ghaith AK, Khalilullah T, Rajasekaran J, Xia Y, Ahmed AK, Azad TD, Yang L, Al-Mistarehi AH  et al.  Surgical Management of Spinal Chondrosarcoma: Retrospective Case Series and Systematic Review of the Literature.  Oper Neurosurg  2026 Jun 03;. doi:10.1227/ons.0000000000002086
  15. Habashy KJ, Arrieta VA, Haupt B, Gómez M, El-Hajj VG, Kim KS, Dmello C, Chen L, Carpentier A, Canney M  et al.  Development of skull-implanted ultrasound for blood-brain barrier opening and drug delivery in neuro-oncology.  Neurooncol Adv  2026 Jun;8(Suppl 4):iv9-iv19. doi:10.1093/noajnl/vdaf044
  16. Mejia-Bautista M, Loxas M, Jamshidi P, Duckett D, Wolinsky JP, Ahrendsen JT  A 40-year-old woman with a spinal mass.  Brain Pathol  2026 Jun 01;:e70111. doi:10.1111/bpa.70111
  17. Duffy JT, Martin-Regalado A, Haupt BE, Pogue JR, Thakur A, Cota MF, Zannikou M, Misener S, Krymskaya VP, McCortney K  et al.  Fully Humanized Bispecific T Cell Engager Shows Potent Activity in Central Nervous System and Peripheral Tumors.  Adv Sci (Weinh)  2026 Jun;13(35):e22391. pii:e22391
  18. Zhu L, Kinjawadekar I, Prempeh C, Nikonorova IA, Mirek ET, Lopez EM, Jonsson WO, Levy JL, Wang L, Li X  et al.  A metabolic basis for motor deficits in mice lacking BCKDK.  J Nutr Biochem  2026 Jun;152:110275. doi:10.1016/j.jnutbio.2026.110275
  19. Wang Y, Belakhoua S, Yang Y, Serrano J, Horbinski C, Boué DR, DeWitt JC, Liechty B, McGuone D, Mao Q  et al.  Histopathological and molecular heterogeneity of dysembryoplastic neuroepithelial tumors.  J Neuropathol Exp Neurol  2026 May 29;. pii:nlag052
  20. Piña Y, Umeh Garcia M, Boire A, Brenner A, Camidge DR, Chang S, Forsyth PA, Hayden Gephart M, Olayinka Kamson D, Kumthekar P  et al.  Breaking Barriers in Leptomeningeal Disease: A SNO-ASCO Consensus Review on Clinical Trial Design and Basic Science Integration.  Neuro Oncol  2026 May 27;. pii:noag126
  21. Lukas RV, Zhai L, Lauing KL, Kim M, Koch T, Penco-Campillo M, Bommi P, Dixit K, Kumthekar P, Sharp L  et al.  Phase 1 evaluation of patients with newly diagnosed glioblastoma treated with radiation, nivolumab, and IDO1 enzyme inhibitor BMS-986205.  Clin Cancer Res  2026 May 26;. doi:10.1158/1078-0432.CCR-26-1124
  22. Kundu IG, Toro N, Mochizuki AY, Langhnoja J, Ayyagari RV, Cronk JC, Reel SM, Arounleut P, Esqueda LT, Fuller CE  et al.  Murine modeling of IDH-mutant 1p/19q-codeleted oligodendroglioma reveals genotype specific phenotypes.  bioRxiv  2026 May 19;. pii:2026.05.14.725183
  23. Brat DJ, Aldape K, French PJ, Louis DN, Nasrallah MP, Reifenberger G, Reuss DE, Touat M, van den Bent MJ, Wesseling P  et al.  cIMPACT-NOW update 12: Refining Pathology-based Risk Stratification and Grading for IDH-mutant Gliomas.  Neuro Oncol  2026 May 18;. pii:noag108
  24. Basakis P, Shih LK, Li J, Brat DJ  Uncovering a feedback loop in glioblastoma that reinforces stemness and immunosuppression.  J Clin Invest  2026 May 15;136(10). pii:e205841
  25. Yu X, Song X, Schäfer RA, Meng Q, Tiek D, Wu R, He Q, Walker M, Cao Q, Yang R  et al.  An EGFR co-amplified lncRNA HELDR promotes glioblastoma malignancy through KAT7-driven gene programs.  Nat Cell Biol  2026 May;28(5):972-985. doi:10.1038/s41556-026-01924-w
  26. Wu R, Yu X, Song X, He Q, Walker M, Sisbarro D, Horbinski C, Tiek D, Hu B, Zhang N  et al.  Tumor-associated astrocytes augment cholesterol synthesis to support glioblastoma growth through alternatively spliced QKI isoforms.  Neuro Oncol  2026 May 01;28(5):1163-1178. doi:10.1093/neuonc/noag030
  27. Rajan A, Castro FR, de Godoy LL, Hanaoka M, Turk S, Desiderio L, Stupp R, Mohan S, Chawla S  Imaging biomarkers for detecting IDH mutations and monitoring response to novel targeted therapies: Current insights and future perspectives.  Neuro Oncol  2026 May 01;28(5):1101-1116. doi:10.1093/neuonc/noag028
  28. Lassman AB, Polley MC, Iwamoto FM, Gondi V, Sulman EP, Wolchok JD, Mehta MP  Reply to: Blood-Brain Barrier Heterogeneity in NRG BN007: Implications for Immunotherapy Delivery.  J Clin Oncol  2026 May;44(13):1267-1268. doi:10.1200/JCO-25-02821
  29. Visa MA, Liggett MR, Lashley S, Bhatti U, Dawood ZA, Anand A, Gill NP, Scholtens DM, Wang B, Alam HB  Valproic acid for treatment of traumatic brain injury: Study protocol for the VIBRANT prospective randomized trial.  Transfusion  2026 May;66 Suppl 1(Suppl 1):S266-S277. doi:10.1111/trf.70029
  30. Benato A, Texakalidis P, Wolinsky JP  Reconstruction of posterior elements of the spine with femoral shaft allograft after spondylectomy for En bloc resection of tumor.  Eur Spine J  2026 May;35(5):2519-2530. doi:10.1007/s00586-025-09141-z
  31. Khazanchi R, Govind S, Jain R, Vignolles-Jeong J, Munjal V, Chaliparambil R, Damante M, Chandler JP, Ghalib L, Huang W  et al.  Unsupervised clustering analysis reveals distinct postoperative cortisol trajectories following pituitary adenoma resection in Cushing's disease.  J Neurooncol  2026 Apr 30;177(3). pii:132
  32. Luo M, Wu S, Huang C, Zheng Z, Xia Q, Li Y, Zhou X, Hong S, Zhong R, Li W  et al.  Inhibition of PRMT5-dependent YAP methylation attenuates tumorigenicity and radioresistance in glioblastoma.  Cancer Lett  2026 Apr 28;644:218308. doi:10.1016/j.canlet.2026.218308
  33. Jiang K, Al-Mistarehi AH, Zaitoun KJ, Weber-Levine C, Xia Y, Mendelson BZ, Ksabi NL, Papali P, Neerumalla S, Antar A  et al.  Utility of direct wave intraoperative neuromonitoring for intramedullary spinal cord tumor resection.  J Neurosurg Spine  2026 Apr 24;45(1):79-88. doi:10.3171/2025.11.SPINE25124
  34. Lee C, Mille MM, Griffin KT, Rigsby C, Popescu A, Gopalakrishnan M, Leisenring W, Peterson S, Dome JS, Laurie F  et al.  Estimation of Detailed Cardiac Doses for Pediatric Radiation Therapy Patients in National Wilms Tumor Study.  Int J Radiat Oncol Biol Phys  2026 Apr 15;. pii:S0360-3016(26)00570-5
  35. Memon R, Talati R, Song R, Ordon M, Dixit KS, Khan OH  Elevated neutrophil-to-lymphocyte ratio as a prognostic factor in primary central nervous system lymphoma.  Neurooncol Adv  2026;8(1):vdag124. pii:vdag124
  36. Kim H, Gomez A, Dixit KS  First report of a clinical and radiologic response to vorasidenib in a patient with isocitrate dehydrogenase-mutant brainstem astrocytoma.  Neurooncol Pract  2026 Apr;13(2):428-431. doi:10.1093/nop/npaf131
  37. Rodriguez A, Dixit K, O'Hara RM, Vojnic M  Efficacy of tepotinib in patients with high-grade glioma with MET alterations: A case series.  Neurooncol Pract  2026 Apr;13(2):422-427. doi:10.1093/nop/npaf130
  38. Zhao C, Lin Y, Chen H, Liu H, Hu W, Wang X, Chen J, Luo N, Qi X, Han S  et al.  S100A8-associated inflammatory microenvironment is related to its cell-of-origin and potentiates BRAF inhibitor resistance in papillary craniopharyngioma.  Clin Exp Med  2026 Apr 01;26(1). pii:210
  39. Aggarwal A, Youngblood MW, Picart T, Najem H, Oten S, Cady MA, Magill ST, Horbinski CM, Chandler JP, Heimberger AB  et al.  Meningioma cell reprogramming and microenvironment interactions underlie brain invasion.  Neuro Oncol  2026 Apr 01;28(4):926-938. doi:10.1093/neuonc/noaf292
  40. Smith HL, Duckett DJ, Mejia-Bautista M, Alshawa A, Jamshidi P, Castellani RJ, Lukas RV, Chandler JP, Jennings LJ, Santana-Santos L  et al.  IDH-wildtype astrocytoma with FH mutation, epigenetic similarity to IDH-mutant astrocytoma, and hypermethylation of CDKN2A arising in the brainstem.  J Neuropathol Exp Neurol  2026 Apr 01;85(4):398-401. doi:10.1093/jnen/nlaf086
  41. Billingham LK, DeLay SL, Eshac Y, Chia TY, Tripathi S, Olson IE, Zilinger K, Subbiah J, Wang Z, Sadagopan NS  et al.  Microglial fructose metabolism is essential for glioblastoma growth.  Proc Natl Acad Sci U S A  2026 Mar 24;123(12):e2521256123. pii:e2521256123
  42. Lukas RV, Du R, Congivaram H, McCortney K, Dixit K, Horbinski C, Schwartz M, Lezon R, Singer L, Primdahl D  et al.  Consideration of spatial companion biomarkers for targeted therapeutics in cancer: depatuxizumab mafodotin in glioblastoma.  JCI Insight  2026 Mar 23;11(6). pii:e198475
  43. Song R, Dapash M, Jamshidi P, Gondi V, Lukas RV, Khan OH  Survival and function in elderly patients with GBM: the role of surgical resection with contemporary multimodal therapy.  J Neurooncol  2026 Mar 17;177(2). pii:62
  44. Khalilullah T, Yang X, Yao J, Ghaith AK, Khalifeh JM, Azad TD, Ahmed AK, Xia Y, Theodore N, Romo CG  et al.  Malignant peripheral nerve sheath tumors arising in SMARCB1-associated schwannomatosis: illustrative cases.  J Neurosurg Case Lessons  2026 Mar 16;11(11). pii:CASE25610
  45. Colman H, Lombardi G, Wong ET, Walbert T, Eoli M, Lassman AB, Peereboom DM, Kizilbash SH, Kamiya-Matsuoka C, Pitz MW  et al.  STELLAR: Phase III, Randomized, Open-Label Study of Eflornithine Plus Lomustine Versus Lomustine Alone in Patients With Recurrent Grade 3 Astrocytoma.  J Clin Oncol  2026 Mar 10;44(8):641-652. doi:10.1200/JCO-25-01204
  46. Jin Z, Li X, Hou X, Hu J, Zhuo Y, Shi J, Xu T, Zhao Q, Jing Z  Correction: Single-atom Ca nanozyme induces glioma death through Ca2+-overload-enhanced catalytic tumor nanotherapy, ferroptosis and synergistic remodeling of the immune microenvironment.  J Nanobiotechnology  2026 Mar 02;24(1). pii:205
  47. Lee-Chang C  Organized immunity in the CNS: what stroke reveals about neuroinflammation and lymphoid niches.  J Clin Invest  2026 Mar 02;136(5). pii:e202688
  48. Khasraw M, Pristo E, Stupp R  20 years of the Stupp protocol: confronting stagnation in glioblastoma therapy.  Lancet Oncol  2026 Mar;27(3):277-280. doi:10.1016/S1470-2045(25)00705-3
  49. Tiek D, Song X, Wu R, Yu X, Walker M, Mao Y, Sisbarro D, He Q, Magassa A, Singh A  et al.  Cysteine addiction in drug resistant glioblastoma and therapeutic targeting with designer selenium compounds.  Neuro Oncol  2026 Mar 01;28(3):613-625. doi:10.1093/neuonc/noaf265
  50. Tripathi S, Najem H, Hurley L, Du R, Dmello C, Ali H, McCortney K, Habashy KJ, Zhang P, Horbinski CM  et al.  STING-induced blood-brain barrier opening combined with radiotherapy potentiates antitumor response in a high-grade glioma model.  J Clin Invest  2026 Feb 16;136(4). pii:e198843
These are the publications from our team members that have been most recently indexed by PubMed. Visit PubMed to see more of our publications.

Follow MBTI on FacebookYouTubeLinkedInInstagram